In a 12-week, double-blind, placebo-controlled trial of 35 geriatric cats, once-weekly oral PURR-001 produced a 7% average gain in body mass versus 1% on placebo, with epaxial muscle thickness rising 23% against 9% in controls. Hematology, serum biochemistry and adverse event rates were comparable between groups. The developer has signed a European licensing agreement to advance manufacturing and regulatory work, though the compound remains investigational.
Key Points
- Epaxial muscle thickness rose 23% versus 9% on placebo
- Safety markers and adverse events comparable between treatment groups
- Small, short trial; strength and mobility endpoints not measured
Longevity Analysis
Skeletal muscle remains one of the few aging endpoints that is both measurable and directly tied to capability, which is why imaging of specific muscle groups carries more information than total body mass — weight can accumulate in tissues that contribute nothing to movement or metabolic reserve. Distinguishing anatomical gain from functional gain is the central interpretive task here, and the absence of strength, gait or activity data leaves that question open. Companion-animal trials of this design offer a faster read on conserved mammalian aging targets, but the value of the signal depends on whether it persists and whether it restores the ability to move, not merely the mass available to move with.
Original published by Longevity.Technology, by Eleanor Garth.